MR 17	TRANSMITTAL FORM (to be used for all correspondence after initial filling) Total Number of Pages in This Submission	U.S. Pater ons are required to respond to a collection Application Number Filing Date First Named Inventor Art Unit Examiner Name Attorney Docket Number CLOSURES (Check all tha	Approved for use through 04/30/2003. OMB 0651-0031 nt and Trademark Office; U.S. DEPARTMENT OF COMMERCE on of information unless it displays a valid OMB control number. 10/734,949 December 13, 2003 Rodriguez-Sarmiento
	Certified Copy of Priority	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Add Terminal Disclaimer Request for Refund CD, Number of CD(s)	After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below):
	SIGNATURE	OF APPLICANT, ATTORN	NEY, OR AGENT
		FICATE OF TRANSMISSIO and to the USPTO or deposited with the Us, P.O. Box 1450, Alexandria, VA 223	United States Postal Service with sufficient postage as first class

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Serial No. 10/734,949 Filed: December 13, 2003

Since the Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits or within three months of the filing date for the above application no fee is due.

Respectfully submitted,

Attorney for Applicant(s)

Kimberly J. Prior (Reg. No. 41,483) 340 Kingsland Street

Nutley, New Jersey 07110 Telephone: (973) 235-6208

Telefax: (973) 235-2363

139361

SEMENTE OF FORM 1449A/PTO INFORMATION BISCLOSURE STATEMENT BY APPLICANT MAR 1 7 2004 (Use several sheets innecessary)				Complete if Known				
				Application Number				
				Filing Date		er 13, 2003		
				First Name Inventor	First Name Inventor Rodrigu		ez-Sarmiento	
Sheet	10	of A	,	Attorney Docket Number	21247 L	JS		
	Cin	(THINGS	U.S. PA	TENT DOCUMENTS				
		U.S. Patent D	ocument			D . CD !!! .!		
Examiner Initials'	Cite No.'		Kind Cod	Name of Patentee or Applicant of Cited Document		Date of Publication of Cited document		
IIIIIIais	140.	Number (if know				MM-DD-YYYY		
	A							
	<u> </u>		FOREIGN	PATENT DOCUMENTS				
		Foreign Patent Document				Date of	T ⁶	
Examiner	Cite	Office ³ Number	Kind	Name of Patentee o		Publication of Cited Document		
Initials'	No.'	T. Camber	Code ⁵	Applicant of Cited Docu	ment	MM-DD-YYYY		
	B1	WO 01/34172		Vela Pharmaceuticals	Inc.	05/17/2001	\vdash	
	B2	WO 97/33572		Somerset Pharmaceutic		09/18/1997		
-	B3	WO 96/40095		Harris, R. Y.		12/19/ 1996		
		1						
		NON	PATENT I	LITERATURE DOCUMEN	NTS			
Examiner	Cite	Include name of the	author (in CAP	ITAL LETTERS), title of the article	(when approp	oriate), title of the	T ²	
Initials'	No.1	item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published						
	C1	Bach et al., Proc. Natl. Acad. Sci. Vol. 85: pgs. 4934-4938 (1988)						
	C2	Cesura & Pletscher, Prog. Drug Research Vol. 38: pgs. 171-297						
		(1992)						
	C3	Fowler et al., J. Neural. Transm. Vol. 49: pgs. 1-20 (1980)						
	C4	Benedetti et al., Biochem. Pharmacol. Vol. 38: pgs. 555-561 (1989)						
	C5	Saura et al., Neuroscience Vol. 70: pgs. 755-774 (1996)						
	C6	Bentué-Ferrer et al., CNS Drugs Vol. 6: pgs. 217-236 (1996)						
	C7	Gardner et al. J. Clin. Psychiatry Vol. 57: pgs. 99-104 (1996)						
	C8	Schlaeger & Christensen, Cytotechnology Vol. 30: pgs. 71-83 (1999)						
	C9	Zhou & Panchuk-Voloshina, Analytical Biochemistry Vol. 253: pgs.						
			2 P8					
Examiner	 	169-174 (199 Date Considered	')					
	1							

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Unique citation designation number. *See attached Kinds of U.S. Patent Documents. *Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation or abstract is attached.